Keeping Pace in Women’s Cancer: Focus on Endometrial Carcinoma - a podcast by ReachMD

CME credits: 0.25

Valid until: 21-09-2021

Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-womens-cancer-focus-endometrial-carcinoma/11839/

There remains a critical unmet need for effective therapies following the recurrence of endometrial cancer. In this activity, Drs. Linda Duska and Richard Penson assess the role of immunotherapy and targeted therapies in managing advanced endometrial cancers, as well as the importance of evaluating the microsatellite and mismatch repair biomarker status of recurrent and metastatic endometrial cancer.

Since the release of this activity, the FDA has approved the use of dostarlimab for the treatment of patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR, as determined by an FDA-approved test. Visit the FDA statement dated 22 April 2021 to learn more.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD